190 related articles for article (PubMed ID: 2449352)
1. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
Hetherington JW; Siddall JK; Cooper EH
Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
[TBL] [Abstract][Full Text] [Related]
2. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
4. Systematic association of PAP and PSA determinations to bone scintigraphy in prostatic cancer.
Fincker F; Sauvan R; Pasquier J
Am J Clin Oncol; 1988; 11 Suppl 2():S68-70. PubMed ID: 2468277
[TBL] [Abstract][Full Text] [Related]
5. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
6. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
[TBL] [Abstract][Full Text] [Related]
7. [Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].
Morote J; de Torres JA
Actas Urol Esp; 1990; 14(4):268-70. PubMed ID: 1702258
[TBL] [Abstract][Full Text] [Related]
8. A reappraisal of serial isotope bone scans in prostate cancer.
O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF
Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607
[TBL] [Abstract][Full Text] [Related]
9. [Relation between serum PAP (prostate acid phosphatase) and bone scintigraphy in prostatic cancer].
Aizawa T; Itoh T; Tsujino S; Namiki K; Miki M
Kaku Igaku; 1992 Nov; 29(11):1277-83. PubMed ID: 1484418
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
Miller PD; Eardley I; Kirby RS
Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920
[TBL] [Abstract][Full Text] [Related]
13. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen--a screening test for prostatic cancer?
Powell CS; Fielding AM; Rosser K; Ames AC; Vaughton KC
Br J Urol; 1989 Nov; 64(5):504-6. PubMed ID: 2482112
[TBL] [Abstract][Full Text] [Related]
15. Levels of prostate specific antigen that predict skeletal spread in prostate cancer.
Pantelides ML; Bowman SP; George NJ
Br J Urol; 1992 Sep; 70(3):299-303. PubMed ID: 1384921
[TBL] [Abstract][Full Text] [Related]
16. [The usefulness of early whole body bone scintigraphy in the detection of bone metastasis from prostatic cancer].
Otsuka N; Fukunaga M; Furukawa Y; Tanaka H
Kaku Igaku; 1994 Jun; 31(6):541-50. PubMed ID: 7520953
[TBL] [Abstract][Full Text] [Related]
17. The contribution of prostatic acid phosphatase and prostatic specific antigen in the diagnosis of prostatic cancer.
van Dalen A; Helmhout DH; van Caubergh RD
Int J Biol Markers; 1988; 3(2):123-6. PubMed ID: 2468722
[TBL] [Abstract][Full Text] [Related]
18. Prostate tumour markers as an aid in the staging of prostatic cancer.
Haapiainen RK; Permi EJ; Rannikko SA; Voutilainen PE; Liewendahl K; Stenman UH; Alfthan OS
Br J Urol; 1990 Mar; 65(3):264-7. PubMed ID: 1692497
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Buamah PK; Johnson P; Skillen AW
Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen in management of prostatic carcinoma.
Brawer MK; Lange PH
Urology; 1989 May; 33(5 Suppl):11-6. PubMed ID: 2469244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]